SCHEMBL885845

SCHEMBL885845

CCc1nc2ccccc2n1-c1ncccc1CC(c1cccnc1)c1cccnc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 12/20 0.44
KCNH2 Q12809 4/20 0.44
BMI1 P35226 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
GSR P00390 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
POLB P06746 1/20 0.36
PABPC1 P11940 1/20 0.36
RECQL P46063 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL885741 0.89 KCNA5 (0.46) KCNA5KCNH2GSRTSHRMAPK1
SCHEMBL885624 0.87 KCNA5 (0.43) KCNA5KCNH2TSHRMAPK1
SCHEMBL885612 0.86 KCNA5 (0.51) KCNA5KCNH2MEN1KMT2ATSHR
SCHEMBL886155 0.85 KCNA5 (0.44) KCNA5KCNH2MEN1KMT2ALMNA
SCHEMBL885958 0.85 KCNA5 (0.52) KCNA5KCNH2MAPTTSHRMAPK1
SCHEMBL885582 0.85 KCNA5 (0.46) KCNA5KCNH2TSHRMAPK1
SCHEMBL885038 0.84 KCNA5 (0.53) KCNA5KCNH2MEN1KMT2A
SCHEMBL886144 0.82 KCNA5 (0.47) KCNA5KCNH2KDM4EALDH1A1HPGD
SCHEMBL886251 0.82 KCNA5 (0.48) KCNA5KCNH2KDM4ESMN1; SMN2
SCHEMBL886404 0.82 KCNA5 (0.44) KCNA5KCNH2KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US claimed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP claimed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO claimed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885BMI1 3833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.